Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
Leading Pediatrics Hospital Finds Rapid Testing Reduces Unnecessary Use of Antibiotics
In a five-year study, VERIGENE® BC-GP Test shrinks time to results by as much as 24 hours
In a new publication, medical professionals from Children’s Hospital Los Angeles and the University of Southern California report results from a comprehensive five-year study of the VERIGENE® Gram-Positive (BC-GP) Blood Culture Test. They found that the “[VERIGENE] BC-GP panel demonstrated excellent performance” and that its reliable detection of genes conferring drug resistance allows healthcare providers to “confidently de-escalate antimicrobial therapy” when appropriate, according to the paper.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
September 11
Luminex Corporation Declares Third Quarter Cash Dividend
September 6
Luminex Corporation to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
August 6
Luminex Corporation Reports Second Quarter 2018 Financial Results
July 13
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018
June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
Microbe UK
21-23 September
Sheffield, UK
World Vaccine Congress
29-31 October
Lisbon, Portugal
xMAP® Connect Amsterdam
6-7 November
Amsterdam, Netherlands
